Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells

Breast Cancer Research and Treatment

Volumn 94, Issue 1, 2005, Pages 47-52

  Andrews, Heather N ^a   Habibi, Golerah ^a   Kucab, Jill E ^a   Dunn, Sandra E ^a,b  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

Akt; Celecoxib; Erk; MDA MB 231 breast cancer cells; uPA; Urokinase type plasminogen activator

Indexed keywords

CELECOXIB; UROKINASE RECEPTOR;

ARTICLE; BREAST CALCIFICATION; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL VIABILITY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES; URINARY PLASMINOGEN ACTIVATOR;

EID: 26244463530     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-6941-5     Document Type: Article

References (25)

1. F Janicke M Schmitt K Ulm W Gossner H Graeff 1989 Urokinase-type plasminogen activator antigen and early relapse in breast cancer Lancet Oct 28 1049
2. MP Look 2002 Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 2 116 128
3. DH Nguyen DJ Webb AD Catling Q Song A Dahkephalkar KT Weber KS Ravichandran SL Gonias 2000 Urokinase-type plasminogen activator stimulates the ras/extracellular signal-regulated kinase (erk) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, src and shc J Biol Chem 275 25 19382 19388
4. HR Yu RM Schultz 1990 Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes Cancer Res 50 23 7623 7633
5. Y Guo AP Mazar JJ Lebrun SA Rabbani 2002 An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer Cancer Res. 62 16 4678 4684
6. MD Wendt TW Rockway A Geyer W McClelland M Weitzberg X Zhao R Matei VL Neinaber K Stewart V Lkinghofer VL Giranda 2004 Identification of novel binding interactions in the deelopment of potent, selective 2-naphthamidine inhibitors of urokinase Synthesis, structural analysis, and SAR of n-phenyl amide 6-substitution J Med Chem 47 2 303 324
7. SE Dunn JV Torres JC Barrett 2001 Up-regulation of urokinase type plasminogen activator by insulin-like growth factor-1 depends upon phosphotidyl inositol-3 kinase and Map kinase kinase Cancer Res 61 Feb 15 1367 1374
8. T Nielsen H Andrews M Cheang JE Kucab FD Hsu J Ragaz CB Gilks N Makretsov CD Bajdik C Brookes LM Neckers V Edvokimova D Huntsman SE Dunn 2004 Expression of the insulin-like growth factor-1 receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17 allylamino 17-demethoxy geldanamycin Cancer Res 64 Jan 1 286 291
9. LR Howe K Subbaramaiah J Patel JL Masferrer A Deora CA Hudis HT Thaler WJ Muller AM Brown AJ Dannenberg 2002 Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor 2 (Her-2)/neu induced breast cancer Cancer Res 62 19 5405 5407
10. RE Harris GA Alshafie H Abou-Issa K Seibert 2000 Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor Cancer Res 60 8 2101 2103
11. N Kundu AM Fulton 2002 Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer Cancer Res 62 8 2343 2346
12. RJ Levitt J Buckley MJ Bouin B Schaub TJ Triche M Pollak 2004 Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression Biochem Biophy Res Comm 316 2 421 428
13. A Hsu TT Ching D Wang X Song VM Rangnekar CS Chen 2000 The cyclooxygenase-2 inhibitor Celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of BCL-2 J Biol Chem 275 Apr 14 11397 11403
14. AJ Johnson X Song A Hsu CS Chen 2001 Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer Adv Enzyme Regul 41 221 235
15. J Zhu X Song HP Lin DC Young S Yan VE Marquez CS Chen 2002 Using cyclooxygenase 2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents J Natl Cancer Inst 94 23 1745 1757
16. SK Kulp YT Yang CC Hung KF Chen JP Lai PH Tseng JW Fowble PJ Ward 2004 Chen CS, 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells Cancer Res 64 Feb 15 1444 1451
17. XH Liu DP Rose 1996 Differential expression and regulation of cyclooxygenase 1 and 2 in two human breast cancer cell lines Cancer Res 22 Nov 15 5125 5127
18. PB Mullan JE Quinn PM Gilmore S McWilliams H Andrews C Gervin N McCabe S McKenna P White YH Song S Maheswaran ET Liu DA Haber PG Johnston DP Harkin 2001 BRCA-1 and GAdd45 mediated G2/M cell cycle arrest in response to antimicrotubule agents Oncogene 20 43 6123 6131
19. JS Oh P Buchel K Martin JE Kucab T Oshimura L Bennett JC Barrett RP DiAugustine C Afshsari SE Dunn 2002 Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells Neoplasia 4 3 204 217
20. HN Andrews PB Mullan S McWilliams S Sebelova JE Quinn PM Gilmore N McCabe A Pace B Koller PG Johnston DA Haber DP Harkin 2002 BRCA-1 regulates the interferon gamma-mediated apoptotic response J Biol Chem 277 29 26225 26232
21. CL Sawyers 2002 Rational therapeutic intervention in canccer: kinases as drug targets Curr Opin Genet Dev 12 1 111 115
22. G Li T Yang J Yan 2002 Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells Biochem Biophy Res Comm 299 5 886 890
23. DH Berger CA O'Mahony H Sheng J Shao D Albo RN Dubois RD Beauchamp 2003 Intestinal transformation results in transforming growth factor best dependent alteration in tumor cell-cell matrix interactions Surgery 133 5 568 579
24. K Brune A Neubert 2001 Pharmacokinetic and pharmacodynamic aspects of the ideal Cox-2 inhibitor: a pharmacologists perspective Clin Exp Rheumatolo 19 Suppl 25 S51 S57
25. MB Terry MD Gammon FF Zhang H Tawfik SL Teitelbaum JA Britton K Sabbaramaiah AJ Dannenberg AI Neugut 2004 Association of frequency and duration of aspirin use and hormone receptr status with breast cancer risk JAMA 291 2 2433 2440